Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”

PHILADELPHIA, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted an article from Corporate America News magazine, released on...
July 11, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Updates the Status of the Alferon® Manufacturing Facility

PHILADELPHIA, July 11, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) in response to various questions about the status of the work to repair damage to our Alferon®...
January 20, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has...
October 19, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
August 27, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey

NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the...
August 19, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reminder Regarding Stockholder Open House at Manufacturing and Research Facility in New Jersey

PHILADELPHIA, Aug. 19, 2015 (GLOBE NEWSWIRE) -- As previously announced and provided in the proxy materials, the Management and the Board of Directors of Hemispherx Biopharma (NYSE MKT:HEB) will host...
August 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection(R)

PHILADELPHIA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that as the Company works toward the re-launch of Alferon N, it has...
August 11, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Expands Its Collaboration With Emerge Health for the Commercialization of Alferon in Australia and New Zealand

PHILADELPHIA, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
July 15, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection(R) for Treatment of Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that they have submitted an application for orphan drug designation...
May 20, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx to Present at the Marcum Microcap Conference in New York

PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...

Next Page keyboard_arrow_right